We tested a selected series of patients with single urothelial high-grade pT1 stage (pT1 HG) or urothelial carcinoma in situ (CIS) with a set of immunohistochemical markers to elaborate a risk score for progression. We retrospectively reviewed all first diagnoses of single, <3 cm, urothelial papillary carcinoma pT1 HG or isolated CIS between 2006 and 2009. Galectin-3, CD44, E-cadherin, CD138, p16, survivin, HYAL-1, and topoisomerase-II a were used. A grading score 0 or 1 for each immunohistochemical staining was assigned to obtain a total score for assessing the progression. The median "progression score" was selected as cutoff value for statistical analysis. Overall, 23 patients (19 pT1 HG and 4 CIS) were included in the study. After a median follow-up of 21 months (range, 12 to 34 mo), 9 patients (39.1%) showed disease recurrence whereas 4 patients (17.4%) showed tumor progression. Topoisomerase-II a, p16, survivin, galectin-3, and CD138 were significantly associated with progression. Progression score ranged from 0 (best prognosis) to 7 (worst prognosis). Using a score Z5 as a threshold, specificity was 78.9%, sensitivity 100%, positive predictive value 50%, and negative predictive value 100%. ROC area (a 95% confidence interval, 0.807-1.000; P < 0.001). This immunohistochemistry-based progression score using a threshold Z5, might help the clinician to focus on patients with HG pT1 or extended CIS at high risk for disease progression. These patients might benefit from a more intensive follow-up program or early cystectomy.
T he single most important prognostic factor in urothelial carcinoma is pathologic stage; major therapeutic decisions being made on the anatomic depth of invasion. Similar to noninvasive tumors, a carcinoma confined to lamina propria is usually treated conservatively. However, approximately 75% of those patients with urothelial carcinoma confined to lamina propria experience tumor recurrence within 2 years of transurethral resection (TUR-BT), and more importantly, 25% of the patients experience progression to invasive disease that can be associated with poor prognosis. 1 Similar to pT1 high-grade (HG) tumors, carcinoma in situ (CIS) can also progress to muscle-invasive disease and, without any treatment, the risk of progression have been reported in approximately 54% of patients. 2 Unfortunately there are no reliable prognostic factors that can be used to predict the course of pT1 HG bladder carcinoma and CIS specifying the most dangerous cases. The EORTC scoring system has been developed to predict cancer recurrence and progression of pTa and pT1 bladder tumors and the variables included are the number of tumors, tumor diameter, time to recurrence, T stage, the association with CIS and grade, and has confirmed its prognostic validity. 3 However, according to the EORTC scoring system, a single urothelial pT1 HG urothelial carcinoma of the bladder at first diagnosis, <3 cm in greatest diameter, cannot be further stratified into prognostic categories, but its behavior is not predictable with a nearly 35% probability of recurrence and 10% probability of progression at 24 months of follow-up.
Urothelial bladder cancer and CIS are characterized by the presence of several genetic alterations involving multiple different chromosomal regions. Many markers have been investigated to predict the biological behavior of bladder carcinoma and CIS, but none of the proposed markers by itself has been clearly associated neither with tumor recurrence nor with progression to muscle-invasive tumors, and none have been included into the clinical management algorithm. Therefore, we have tested a series of cases with a set of immunohistochemical markers to evaluate whether their expression can be useful for the management of patients with pT1 HG and CIS. Eventually we elaborated a risk score for tumor progression made from the association of the prognostic ability of each immunohistochemical marker.
MATERIALS AND METHODS

Patients
We retrospectively reviewed all cases of urothelial papillary carcinoma pT1 HG and CIS diagnosed between 2006 and 2009. The cases were included in the study with the following histologic and clinical conditions:
Histologic diagnosis of HG papillary urothelial carcinoma pT1 with tumor size <3 cm or histologic diagnosis of CIS in multiple sites with presence of muscularis propria at the first TUR-BT. The slides and tissue blocks of all TUR-BT specimens (first TUR-BT and follow-up biopsies/TUR-BTs) and all cystectomy specimens were reviewed to confirm the histologic diagnosis and were used for further immunohistochemical analyses.
Recurrence was defined as the finding of new nonmuscle-invasive lesions after a complete resection and an induction course with BCG, whereas progression was defined as the occurrence of muscle-invasive lesions after TUR-BT and BCG instillations.
Tissue Specimens and Immunohistochemistry
The specimens were fixed in 10% formalin before being processed in paraffin. Hematoxylin-eosin-stained sections from each histologic specimen were reviewed to confirm the histologic diagnosis of HG urothelial carcinoma or CIS. The slides and tissue blocks from first TUR-BTs were used for the immunohistochemical analyses.
The following immunohistochemical markers were evaluated: galectin-3, CD44, E-cadherin (E-CAD), CD138, p16, survivin, HYAL-1, and topoisomerase-II a (TOP-2a). Table 1 summarizes the features of the antibodies tested.
The primary antibodies anti-galectin-3 (clone 9C4; Ventana, Tucson, AZ), anti-CD44 (H-CAM) (clone DF1485; Dako, Carpinteria, CA), anti-E-CAD (clone ECH-6), anti-CD138/Syndecan-1 (clone B-A38), and anti-p16 INK4a CINtec Histology V-kit (clone E6H4, ready to use; mtm laboratories, Heidelberg, Germany) were placed on the slides and incubated in Ventana Bench-Mark XT. Additional serial sections were immunostained with rabbit monoclonal antisurvivin clone EP2880Y (Epitomics Burlingame, CA), anti-Hyal-1 rabbit polyclonal (Sigma-Aldrich, St. Louis, MO), and anti-TOP-2a mouse monoclonal (Santa Cruz Biotechnology, Santa Cruz, CA). All sections were performed with antigen retrieval by calibrated water bath capable of maintaining the Epitope Retrieval Solution EDTA (pH 8.0) at 971C for 15 minutes. To block endogenous peroxidase activity, slides were treated with 3.0% hydrogen peroxidase in distilled water for 10 minutes. All antibodies were incubated for 1 hour at room temperature. The immunohistochemical analyses was performed using the streptavidin-biotin peroxidase complex (UltraVision, LabVision, Fremont, CA), and 3,3 0 -diaminobenzidine (DAB) (Dako) as chromogen.
Sections of strongly positive tonsil (CD138), papillary carcinoma of thyroid (galectin-3), lung adenocarcinoma (E-CAD), colorectal adenoma (CD44), urinary bladder carcinoma (survivin), endometrial glands (HYAL-1), and uterine cervix carcinoma (TOP-2a) were used as positive controls. Negative control was performed by substituting the primary antibody with a nonimmune serum at the same concentration. The control sections were treated in parallel with the samples. The sections were lightly counterstained with Mayer's hematoxylin.
Evaluation of Immunohistochemical Staining
The stains for HYAL-1 and galectin-3 were considered positive if any cytoplasmic staining was seen in the neoplastic tissue. A cytoplasm staining with a membranous-reinforced staining pattern was required for considering CD138 positivity ( Fig. 1) . A membrane staining was required for E-CAD and CD44 ( Fig. 2A ). The stains for survivin and TOP-2a were considered positive if nucleus staining was seen in the neoplastic tissue. For survivin, we evaluated only the nuclear-labeling index as previous studies demonstrated the nuclear positivity of this marker to be a prognostic tool for Ta/T1 urothelial carcinoma of the bladder. 4 The stains for p16 were considered positive if nucleus and cytoplasm or only nucleus staining was seen in the tumor cells. For galectin-3, CD44 (Fig. 2B) , and E-CAD we used the von Brunn nests as positive internal control, whereas for the other markers we used the von Brunn nests as negative internal control. 
Slide Grading
All slides were evaluated by an experienced uropathologist in a blinded manner. For semiquantitative assessment of the immunohistochemical data, the mean percentage of positive tumor cells was determined at Â 400 magnification for each section. Sections were graded on the basis of the percentage of tumor cells as 0 (negative), 1 (< 10%), 2 (10% to 49%), and 3 (> 50%). The intensity of staining was graded as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong) (Fig. 3) . The grades for the percentage of tumor cells and staining intensity were multiplied to generate weighted points for each tumor specimen. The weighted points ranged between 0 and 9. Briefly, the weighted points of tumor cell expression were evaluated using the following scoring system: 0 (weighted points between 0 and 3) = weak or no staining and 1 (weighted points between 4 and 9) = moderate/intense staining. Samples with a moderate or strong immunostaining were considered "positive," and samples with a weak or absent immunostaining, "negative."
Score for Assessing the Progression of Bladder Carcinoma (Progression Score)
We assigned a grading score 0 or 1 to each immunohistochemical staining. For each patient, we added the grading score of the 8 immunohistochemical markers to reach a score for assessing the progression (progression score). We attributed a grading score to each patient according to Table 2 . With this approach we obtained the progression score with the addition of all single points.
Statistical Analysis
The impact on disease progression (no recurrence and recurrence vs. progression) of the grading system was evaluated according to the Fisher exact test. A P value <0.05 was considered statistically significant. We evaluated the sensitivity and specificity of the progression score with the ROC curve (MedCalc Software, Mariakerke, Belgium). The median value of the progression score was selected as a threshold for the statistical analyses.
RESULTS
Pathologic and Clinical Features
We evaluated the specimens from TUR-BT of 23 patients with first diagnosis of single HG urothelial carcinoma (pT1 HG) <3 cm in greatest diameter or extended CIS. Median age at intervention was 67 years (range, 50 to 89 y). Overall, 19 patients were male and 4 were female. Of the 23 cases, 19 (82.6%) had a diagnosis of pT1 HG and 4 (17.4%) were diagnosed with extended CIS in multiple sites.
After a median follow-up of 21 months (range, 12 to 34 mo), 10 patients (43.5%) did not show recurrence and/ or progression of the disease; 9 patients (39.1%) showed disease recurrence whereas 4 patients (17.4%) showed tumor progression. All patients with progression to muscle-invasive bladder carcinoma had radical cystectomy. Median time to recurrence was 13 months (range, 4 to 48 mo)and median time to progression was 17 months (range 4 to 23 mo).
Immunohistochemistry: Slide Grading
TOP-2a (P = 0.037), p16 (P = 0.024), survivin (P = 0.04), galectin-3 (P = 0.04), and CD138 (P = 0.037) were associated with the risk of progression according to the Fisher exact test. 
Progression Score
On the basis of the addition of the single grading score of each immunohistochemical marker, a progression score was calculated for each patient (Fig. 8) . Results ranged from 0 (best prognosis) to 7 (worst prognosis). The progression score for E-CAD was 0 in all the cases (Fig. 9 ). All cases with disease progression got a score >5. Taking a score Z5 as a threshold, the specificity was Score for Assessing Progression in pT1 HG Urothelial Carcinoma 78.9%, sensitivity 100%, the positive predictive value 50%, and the negative predictive value 100%. The ROC curve taking this cutoff ( Fig. 10) gave an area under the curve of 0.974, a 95% confidence interval of 0.807-1.000 for a P value <0.001.
DISCUSSION
In this study, we have proposed an immunohistochemistry-based score to predict the progression of single pT1 HG bladder urothelial carcinoma or extended CIS. The score is based on the combination of different markers, which have been shown singularly to have a prognostic impact on disease progression. The assessment of this panel of immunohistochemical markers in urothelial T1 HG carcinomas or CIS specimens improves the ability to predict the risk of disease progression. This score may help to better stratify the heterogeneous population of patients with pT1 HG and/or CIS into risk groups that can be used in combination with other prognostic elements 3, 5, 6 to titrate the clinical decision. The EORTC scoring system has been developed to predict cancer recurrence and progression of pTa and pT1 bladder tumors and the variables included are the number of tumors, tumor diameter, time to recurrence, T stage, the association with CIS and grade, and it has confirmed its prognostic validity. 3 However, according to the EORTC scoring system, a single urothelial pT1 HG urothelial carcinoma of the bladder at first diagnosis, <3 cm in greatest diameter, cannot be further stratified into prognostic categories. Therefore, according to EORTC tables, all our patients have had a homogenous risk of recurrence and progression. The differentiation of patients through selective markers in a homogenous class of risk may detect those patients at higher risk of progression. Negative X Positive X
In the attribution of the grading score, we followed the criteria of the loss of differentiation in the progression of tumor. FIGURE 4. TOP-2a staining: A, grade 1 (< 10%); B, grade 2 (10% to 49%) and negative von Brunn nest (arrow); C, grade 3 (> 50%).
The following markers were evaluated: TOP-2a, p16, CD44, survivin, galectin-3, CD138, HYAL-1, and E-CAD.
TOP-2a, a DNA gyrase isoform plays an important role in the cell cycle and catalyzes the isomerization of DNA by facilitating the passage of 1 strand of DNA through a reversible break in the second strand DNA. Deregulation or qualitative alterations of the TOP-2a expression during the cell cycle have been reported in both normal tissue and various human neoplasms. 7, 8 Enhanced expression of TOP-2a is positively associated with a high rate of recurrence and progression in primary nonmuscleinvasive bladder cancer. 9 Loss and overexpression of p16 protein can affect carcinogenesis and progression of malignancy, and both have been described in urothelial carcinoma. 10 Recent reports demonstrated a high incidence of p16 overexpression in HG urothelial carcinomas and in aggressive subtypes such as the small cell carcinoma and the plasmacytoid urothelial carcinoma. 11, 12 In urinary bladder transitional carcinoma, CD44 expression parallels that of other cell adhesion molecules and progressive loss of immunoreactivity has been observed in association with tumor dedifferentiation and advancing pathologic stage, 13 and its low expression has been reported to correlate with the poor prognosis of bladder tumors in long-term follow-up studies. 14 Survivin is a 16.5 kDa protein that belongs to the inhibitor of apoptosis family and that is undetectable in normal differentiated adult tissue. 15 A recent report underlines that high survivin expression is a marker of tumor aggressiveness and can help identify a subgroup of patients with T1 bladder cancer at a high risk for recurrence. 16 Galectin-3 is a pleiotropic carbohydrate-binding protein that constitutes the basis for cell to cell and cell to matrix interactions and cancer progression. Modulation of galectin-3 expression has been reported in several cancer cell lines with contradictory results. 17, 18 These observations lead to the recognition of galectin-3 as a Score for Assessing Progression in pT1 HG Urothelial Carcinoma diagnostic and prognostic marker for specific cancer types. However, other studies indicated no correlation, 19 or an inverse correlation 20 between the aggressiveness of some tumors and galectin-3 expression. Contradictory results have been also reported regarding the prognostic role of galectin-3 expression in bladder carcinoma. [21] [22] [23] CD138, a member of the family of transmembrane heparin sulfate proteoglycans, plays important roles in epithelial tumor development. 24 In fact, CD138 enhances breast cancer progression, 25 it participates in the process of androgen-dependent to androgen-independent conversion of prostatic carcinoma, 26 and its expression has been FIGURE 6. Survivin staining: A, grade 1 (< 10%); B, grade 2 (10% to 49%); C, grade 3 (> 50%). associated with extracapsular invasion of the thyroid carcinoma. 27 In urothelial bladder carcinoma, it contributes to cell survival and progression, 28 and aggressive subtype of urothelial bladder carcinoma, such as plasmacytoid urothelial carcinoma shows a strong CD138 expression. 12 Hyaluronidase is an endoglycosidase that degrades hyaluronic acid into small angiogenic fragments. Currently, 3 human hyaluronidase genes have been identified. 29 Bladder tumor-derived hyaluronidase is the HYAL1 type. HYAL1 activity in malignant bladder tissues has been reported and its activity has been shown to increase in HG tumors. 30 Among the genetic alterations, the different expression of the cadherin family seems to have a link with bladder cancer. The cadherin family includes N-, P-, and E-cadherin (E-CAD). Only E-CAD, a 120 kDa glycoprotein, the gene of which is located on chromosome 16, is associated with intracellular proteins called catenins that mediate between extracellular signals and cytoskeleton microfilaments. The loss of E-CAD expression is Score for Assessing Progression in pT1 HG Urothelial Carcinoma associated with a loss of cellular differentiation and increased cellular invasiveness, and it may correlate with muscle involvement and tumor recurrence. Loss of E-CAD is also described in aggressive subtype of urothelial carcinoma of the bladder. 31 The progression score was calculated simply by adding the grading score of each immunohistochemical marker, obtaining a score that ranged between 0 (best prognosis) and 7 (worst prognosis). A score Z5 (median progression score) demonstrated a specificity, sensitivity, positive predictive value, and negative predictive value for progression of 78.9%, 100%, 50%, and 100% respectively. The ROC curve at this cutoff gave an area under the curve of 0.974 and a 95% confidence interval of 0.807-1.000 for a P value <0.001.
We are aware that this study is a preliminary report and it should be substantiated by a larger series of cases. Moreover, it includes both single pT1 HG tumors and extended CIS. However, both categories have a substantial risk of recurrence and progression and the progression score applied in the present study might help the clinician to focus on patients at high risk for disease progression. These patients might benefit from a more intensive follow-up program or might be candidates for early cystectomy.
